drug discovery

Europe's IMI Sets Pace for Public/Private Partnerships in Pharmaceutical Development

A recent PharmaTimes article highlighted the efforts of the largest public/private partnership in the pharmaceutical industry, Europe’s Innovative Medicines Initiative (IMI).  The IMI, jointly funded for 2 billion euros by the European Commission and the industry group, the European Federation of Pharmaceutical Industries and Associations (EFPIA), seeks to address the development and delivery issues for …

Europe's IMI Sets Pace for Public/Private Partnerships in Pharmaceutical Development Read More »

Italy's D3 Unites Pharmaceutical Industry, Academia for Public Health

A report in yesterday’s Pharma Letter illustrates how critical partnerships between the pharmaceutical industry and academia can be beneficial for patients, medical professionals and the pharmaceutical industry alike. The Italian Institute of Technology’s Drug Discovery and Development Unit (D3) “brings together scientists with experience in industry and academia to discover new drugs in pain, inflammation …

Italy's D3 Unites Pharmaceutical Industry, Academia for Public Health Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three

Key Opinion Leaders Help to Foster Robust, Viable Pharmaceutical and Biotechnology Pipelines Imagine a world where pharmaceutical and biotechnology companies developed therapies without input from KOLs at various stages of product discovery and development. The results would be far fewer treatments available, greater risks for unwanted side effects and potentially, a larger number of unnecessary …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three Read More »